Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials

Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC–MS/MS

(2016) Paul Severin et al.   Bioanalysis

Membrane Anchor of Cytochrome P450 Reductase Suppresses the Uncoupling of Cytochrome P450

(2015) Masayoshi Miyamoto et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse

(2014) Julia Dinger et al.   TOXICOLOGY LETTERS

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

(2011) Suzanne Leijen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data

(2010) I Templeton et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS